Ascentia Biomedical Corporation Announces New Laboratory and Office Space; Adds Dr. Peter Klein, Renown Pharmaceutical Chemist to Its Staff BELLEVUE, Wash., July 25 /PRNewswire-FirstCall/ -- Ascentia Biomedical Corporation (OTC Pink Sheets: ASCE), a leading researcher and developer of efficacious pharmaceuticals, compounds and other products, announces the lease of office and laboratory space in West Park Business Center in Redmond, WA. Dr. James Clagett, President and CEO of Ascentia said, "We are pleased to have a new facility that is in excess of 6,000 square feet of office and laboratory space with ample room for expansion. This new complex offers improved facilities, which will house our future state-of-the-art laboratory and equipment to afford us the ability to get our in-house research and development programs underway. Importantly, it will permit Ascentia to increase its capacity for pre-clinical contract research, which brings added revenue to support operations. It will provide our outstanding team of researchers an environment in which to excel." Ascentia has also added a new member to its on-staff scientific team. Dr. Peter Klein joins Ascentia Biomedical to oversee its chemistry division where he will spearhead the Company's efforts in the development of anti-tumor and anti-inflammatory therapeutics. In addition, Dr. Klein will bring added opportunities for generation of revenues by increasing the scope of pre- clinical contract research services provided to clients. He has 13 years of pharmaceutical R&D experience including 8 years directing the discovery chemistry program at Cell Therapeutics where he led projects in the discovery and development of oncology and immunology therapeutics and drug delivery systems. He also has served as a consultant for the pharmaceutical industry including the discovery of agents to treat central nervous system disorders. Dr. Klein began his career as a research investigator with the Department of Medicinal Chemistry at the University of Washington following a Ph.D. in synthetic organic chemistry and a B.Sc. in chemistry and cell biology both from the University of Washington. He holds 44 issued pharmaceutical patents. About Ascentia Biomedical Corporation Our focus is SOLUTIONS through RESEARCH and DISCOVERY. Ascentia is developing and commercializing new pharmaceutical and biomedical products for application in a number of areas, including treatment for asthma, arthritis, psoriasis and cancer. Initially, a majority of these products will be secured through direct purchase or through licensing. As the Company grows and evolves, more products will be developed internally. Ascentia is focused on therapies for cancer and diseases of inflammation. For more information visit the Company's website at: http://www.ascentiabiomedical.com/ Certain statements contained herein are "forward looking" statements as such term is defined in the Private Securities Litigation Reform Act of 1995. Because statements include risks and uncertainties, actual results may differ materially from those expressed or implied and include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission. DATASOURCE: Ascentia Biomedical Corporation CONTACT: Dr. James Clagett, President & CEO of Ascentia Biomedical Corporation, +1-425-462-5686; or Jim Drewitz, Investor Relations, +1-972-355-6070, for Ascentia Biomedical Corporation Web site: http://www.ascentiabiomedical.com/

Copyright